Reviewing Strongbridge Biopharma plc (SBBP)’s and Intec Pharma Ltd. (NASDAQ:NTEC)’s results

Both Strongbridge Biopharma plc (NASDAQ:SBBP) and Intec Pharma Ltd. (NASDAQ:NTEC) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Strongbridge Biopharma plc 18.03M 15.98 31.85M -1.63 0.00
Intec Pharma Ltd. N/A 0.00 43.54M -1.40 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Strongbridge Biopharma plc and Intec Pharma Ltd.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Strongbridge Biopharma plc 176.65% 0% -60.6%
Intec Pharma Ltd. 0.00% 0% 0%

Institutional and Insider Ownership

The shares of both Strongbridge Biopharma plc and Intec Pharma Ltd. are owned by institutional investors at 75.1% and 39.64% respectively. Insiders owned 10.17% of Strongbridge Biopharma plc shares. On the other hand, insiders owned about 11.81% of Intec Pharma Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Strongbridge Biopharma plc 6.88% 12.58% 2.72% -7.37% -28.16% 17.86%
Intec Pharma Ltd. -5.95% 4.85% 37.69% 116.32% 34.75% 9.02%

For the past year Strongbridge Biopharma plc has stronger performance than Intec Pharma Ltd.

Summary

Strongbridge Biopharma plc beats on 6 of the 8 factors Intec Pharma Ltd.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.